Franz Humer, CEO of the Roche Group, need to choose whether to install a antagonistic tender offer for the publicly-owned shares of the Roche's biotechnology subsidiary, Genentech.
The case scenario offers chances to evaluate Roche's method with regard to Genentech, the benefits and drawbacks of combining the 2 business with various cultures, the value of Genentech, and the strategies of a hostile tender offer.
Roche's Acquisition of Genentech case study solution
PUBLICATION DATE: February 26, 2010 PRODUCT #: 210040-HCB-ENG
This is just an excerpt. This case is about FINANCE & ACCOUNTING
Related Case Solutions & Analyses:
Dunlap Corporation
India’s Passion for Gold: Velvetcase
Wildcat Capital Investors: Real Estate Private Equity
China Magic Going Home
Fixed Income Arbitrage in a Financial Crisis (D): TED Spread and Swap Spread in May 2009
First American Bank: Credit Default Swaps
Debt Policy at UST, Inc., Spanish Version
Fannie and Freddie and FInancing the American Dream
Saevig Corp.
Methods of Intellectual Property Valuation
